| Next 10 |
Ad
CBAY News and Press CymaBay Therapeutics Inc.
-
NEWARK, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need announced the closing, on January 26, 2023, of its previously a...
-
CymaBay Therapeutics ( NASDAQ: CBAY ) announces the pricing the previously announced public offering of common stock and pre-funded warrants. The company to sell 10M shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. ...
-
CymaBay Therapeutics ( NASDAQ: CBAY ) +7.6% aftermarket on Monday announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by CymaB...
-
CymaBay Therapeutics ( NASDAQ: CBAY ) has entered into a collaboration and license pact with Kaken Pharmaceutical for the development and commercialization in Japan of CymaBay's investigational drug seladelpar for the treatment of primary biliary cholangitis. The advances str...
-
Advances strategy to partner seladelpar for PBC outside U.S. Brings in approximately $34.0 million upfront payment Japan represents an important market with no currently approved second line treatment NEWARK, Calif. and TOKYO, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Cy...
-
Summary 100% technical buy signals. 13 new highs and up 84.95% in the last month. Wall Street price targets from $8 to $14. The Chart of the Day belongs to the biopharma company CymaBay Therapeutics (CBAY). I found the stock by using Barchart's powerful screening funct...
-
CymaBay Therapeutics, Inc. (CBAY) Q3 2022 Earnings Conference Call November 14, 2022 16:30 ET Company Participants Paul Quinlan - General Counsel Sujal Shah - Chief Executive Officer Chuck McWherter - Chief Scientific Officer and President, R&D Dennis Kim...
-
CymaBay Therapeutics press release ( NASDAQ: CBAY ): Q3 GAAP EPS of -$0.28 beats by $0.02 . Held $153.4 million in cash, cash equivalents and investments as of September 30, 2022. For further details see: CymaBay Therapeutics GAAP EPS of -$0.28 beats by $0.02...
-
NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the ...
-
NEWARK, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...
Stock Information
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Get CBAY Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
